Drossman, D. A. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 150, 1262–1279 (2016).

Article  Google Scholar 

Sperber, A. D. et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology 160, 99–114 (2021).

PubMed  Article  Google Scholar 

Mearin, F. et al. Bowel disorders. Gastroenterology 150, 1393–1407 (2016).

Article  Google Scholar 

Vanuytsel, T., Tack, J. F. & Boeckxstaens, G. E. Treatment of abdominal pain in irritable bowel syndrome. J. Gastroenterol. 49, 1193–1205 (2014).

CAS  PubMed  Article  Google Scholar 

Simren, M. et al. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. Gut 67, 255–262 (2018).

PubMed  Article  Google Scholar 

Drossman, D. A. et al. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation Working Team Report. Gastroenterology 154, 1140–1171 (2018).

PubMed  Article  Google Scholar 

Cohen, L. & Neuman, M. G. Cannabis and the gastrointestinal tract. J. Pharm. Pharm. Sci. 23, 301–313 (2020).

PubMed  Article  Google Scholar 

Gotfried, J., Naftali, T. & Schey, R. Role of cannabis and its derivatives in gastrointestinal and hepatic disease. Gastroenterology 159, 62–80 (2020).

CAS  PubMed  Article  Google Scholar 

Nasser, Y., Woo, M. & Andrews, C. N. Cannabis in gastroenterology: watch your head! A review of use in inflammatory bowel disease, functional gut disorders, and gut-related adverse effects. Curr. Treat. Options Gastroenterol. 18, 519–530 (2020).

PubMed  PubMed Central  Article  Google Scholar 

DiPatrizio, N. V. Endocannabinoids in the gut. Cannabis Cannabinoid Res. 1, 67–77 (2016).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Maselli, D. B. & Camilleri, M. Pharmacology, clinical effects, and therapeutic potential of cannabinoids for gastrointestinal and liver diseases. Clin. Gastroenterol. Hepatol. 19, 1748–1758 (2021).

CAS  PubMed  Article  Google Scholar 

Sharkey, K. A. & Wiley, J. W. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology 151, 252–266 (2016).

CAS  PubMed  Article  Google Scholar 

Pesce, M., Esposito, G. & Sarnelli, G. Endocannabinoids in the treatment of gasytrointestinal inflammation and symptoms. Curr. Opin. Pharmacol. 43, 81–86 (2018).

CAS  PubMed  Article  Google Scholar 

Storr, M. A., Yuce, B., Andrews, C. N. & Sharkey, K. A. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol. Motil. 20, 857–868 (2008).

CAS  PubMed  Article  Google Scholar 

Mechoulam, R., Hanus, L. O., Pertwee, R. & Howlett, A. C. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 15, 757–764 (2014).

CAS  PubMed  Article  Google Scholar 

Di Marzo, V. New approaches and challenges to targeting the endocannabinoid system. Nat. Rev. Drug Discov. 17, 623–639 (2018).

PubMed  Article  Google Scholar 

Fowler, C. J., Doherty, P. & Alexander, S. P. H. Endocannabinoid turnover. Adv. Pharmacol. 80, 31–66 (2017).

CAS  PubMed  Article  Google Scholar 

Blankman, J. L. & Cravatt, B. F. Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65, 849–871 (2013).

PubMed  PubMed Central  Article  Google Scholar 

van Egmond, N., Straub, V. M. & van der Stelt, M. Targeting endocannabinoid signaling: FAAH and MAG lipase inhibitors. Annu. Rev. Pharmacol. Toxicol. 61, 441–463 (2021).

PubMed  Article  Google Scholar 

Hill, M. N. & Patel, S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol. Mood Anxiety Disord. 3, 19 (2013).

PubMed  PubMed Central  Article  Google Scholar 

Lutz, B., Marsicano, G., Maldonado, R. & Hillard, C. J. The endocannabinoid system in guarding against fear, anxiety and stress. Nat. Rev. Neurosci. 16, 705–718 (2015).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kaczocha, M., Glaser, S. T. & Deutsch, D. G. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl Acad. Sci. USA 106, 6375–6380 (2009).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Haj-Dahmane, S. et al. Fatty-acid-binding protein 5 controls retrograde endocannabinoid signaling at central glutamate synapses. Proc. Natl Acad. Sci. USA 115, 3482–3487 (2018).

PubMed  PubMed Central  Article  Google Scholar 

Cristino, L., Bisogno, T. & Di Marzo, V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat. Rev. Neurol. 16, 9–29 (2020).

PubMed  Article  Google Scholar 

Abyadeh, M. et al. A proteomic view of cellular and molecular effects of cannabis. Biomolecules 11, 1411 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hua, T. et al. Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures. Cell 180, 655–665 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Krishna Kumar, K. et al. Structure of a signaling cannabinoid receptor 1-G protein complex. Cell 176, 448–458 (2019).

CAS  PubMed  Article  Google Scholar 

Li, X. et al. Crystal structure of the human cannabinoid receptor CB2. Cell 176, 459–467 (2019).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Moreira, F. A., Grieb, M. & Lutz, B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract. Res. Clin. Endocrinol. Metab. 23, 133–144 (2009).

CAS  PubMed  Article  Google Scholar 

Jimenez-Blasco, D. et al. Glucose metabolism links astroglial mitochondria to cannabinoid effects. Nature 583, 603–608 (2020).

CAS  PubMed  Article  Google Scholar 

Soria-Gomez, E. et al. Subcellular specificity of cannabinoid effects in striatonigral circuits. Neuron 109, 1513–1526 (2021).

CAS  PubMed  Article  Google Scholar 

Duncan, M. et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G78–G87 (2008).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Merriam, F. V., Wang, Z. Y., Guerios, S. D. & Bjorling, D. E. Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. Neurosci. Lett. 445, 130–134 (2008).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wright, K. et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129, 437–453 (2005).

PubMed  Article  Google Scholar 

Han, S., Thatte, J., Buzard, D. J. & Jones, R. M. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J. Med. Chem. 56, 8224–8256 (2013).

CAS  PubMed  Article  Google Scholar 

Castro, J. et al. Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents. Pain 163, e72–e86 (2022).

CAS  PubMed  Article  Google Scholar 

Jordan, C. J. & Xi, Z. X. Progress in brain cannabinoid CB2 receptor research: from genes to behavior. Neurosci. Biobehav. Rev. 98, 208–220 (2019).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Howlett, A. C. & Abood, M. E. CB1 and CB2 receptor pharmacology. Adv. Pharmacol. 80, 169–206 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lutz, B. Neurobiology of cannabinoid receptor signaling. Dialogues Clin. Neurosci. 22, 207–222 (2020).

PubMed  PubMed Central